PMID- 28966225
OWN - NLM
STAT- MEDLINE
DCOM- 20180817
LR  - 20180817
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 65
IP  - 1
DP  - 2018 Jan 30
TI  - A case report of fulminant type 1 diabetes mellitus associated with drug-induced 
      hypersensitivity syndrome in an elderly patient with coxsackie B4 virus infection 
      and human leukocyte antigen-A24 haplotype.
PG  - 129-132
LID - 10.1507/endocrj.EJ17-0249 [doi]
AB  - Drug-induced hypersensitivity syndrome (DIHS) is a severe systemic adverse drug 
      reaction. Previous studies showed that DIHS is associated with the onset of 
      fulminant type 1 diabetes mellitus (FT1D). Although genetic background and 
      abnormalities in immune response or viral infection are considered to be 
      associated with pathogenesis of FT1D, it remains unclear whether virus infection 
      and specific human leukocyte antigen (HLA) typing are involved in DIHS-associated 
      FT1D. Here, we report a case of a 78-year-old female patient with FT1D after DIHS 
      treatment. She was diagnosed as DIHS caused by carbamazepine, and treatment with 
      predonisolone was initiated. After 46 days from the occurrence of DIHS, she was 
      admitted to our hospital because of type 1 diabetes mellitus and diabetic 
      ketoacidosis. Although her Hemoglobin A1c (HbA1c) was elevated by predonisolone 
      treatment (HbA1c: 9.2%), we diagnosed her as fulminant type 1 diabetes mellitus 
      considering the abrupt onset of the ketoacidosis. Her general condition was 
      improved by treatment with fluid infusion and insulin administration. During her 
      clinical course, the infection of coxsackie B4 virus was observed. In addition, 
      the examination of HLA typing showed HLA-A24 haplotype. These findings suggest 
      that the coxsackie B4 virus infection may be involved in the pathogenesis of 
      DIHS-induced FT1D, and that HLA-A24 haplotype might relate to DIHS-associated 
      FT1D.
FAU - Takeno, Ayumu
AU  - Takeno A
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Kanazawa, Ippei
AU  - Kanazawa I
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Morita, Miwa
AU  - Morita M
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Takedani, Kai
AU  - Takedani K
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Miyake, Hitomi
AU  - Miyake H
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Yamamoto, Masahiro
AU  - Yamamoto M
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
FAU - Nogami, Kyoko
AU  - Nogami K
AD  - Department of Dermatology, Shimane University Faculty of Medicine, 89-1, 
      Enya-cho, Izumo, Shimane 693-8501, Japan.
FAU - Kaneko, Sakae
AU  - Kaneko S
AD  - Department of Dermatology, Shimane University Faculty of Medicine, 89-1, 
      Enya-cho, Izumo, Shimane 693-8501, Japan.
FAU - Sugimoto, Toshitsugu
AU  - Sugimoto T
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 
      Izumo, Shimane 693-8501, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170929
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticonvulsants)
RN  - 0 (HLA-A24 Antigen)
RN  - 33CM23913M (Carbamazepine)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anticonvulsants/adverse effects
MH  - Blepharospasm/complications/drug therapy
MH  - Carbamazepine/adverse effects
MH  - Combined Modality Therapy
MH  - Coxsackievirus Infections/blood/*complications/virology
MH  - Diabetes Mellitus, Type 1/blood/*complications/therapy/virology
MH  - Diabetic Ketoacidosis/prevention & control
MH  - Drug Hypersensitivity Syndrome/blood/*complications/drug therapy/virology
MH  - Drug Monitoring
MH  - Enterovirus B, Human/*isolation & purification
MH  - Female
MH  - HLA-A24 Antigen/*blood
MH  - Humans
MH  - Japan
MH  - Prednisolone/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Coxsackie virus B4
OT  - Drug-induced hypersensitivity syndrome
OT  - Fulminant type 1 diabetes mellitus
EDAT- 2017/10/03 06:00
MHDA- 2018/08/18 06:00
CRDT- 2017/10/03 06:00
PHST- 2017/10/03 06:00 [pubmed]
PHST- 2018/08/18 06:00 [medline]
PHST- 2017/10/03 06:00 [entrez]
AID - 10.1507/endocrj.EJ17-0249 [doi]
PST - ppublish
SO  - Endocr J. 2018 Jan 30;65(1):129-132. doi: 10.1507/endocrj.EJ17-0249. Epub 2017 
      Sep 29.